ArticleCell death & disease2026
Metabolic activation of LDHA by ERRα represses inflammasome-dependent pyroptosis and promotes ovarian cancer chemoresistance.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoresistance remains a major unmet challenge in the clinical management of ovarian cancer. As a metabolism-associated malignancy, the poor prognosis and frequent chemoresistance of ovarian cancer are closely linked to metabolic reprogramming. In this study, we identify estrogen-related receptor α (ERRα) as a key regulator of metabolic plasticity and chemoresistance in ovarian cancer. Bioinformatic analyses of pan-cancer datasets and chemoresistant ovarian cancer samples reveal that high expression of ERRα and the glycolytic rate-limiting enzyme lactate dehydrogenase A (LDHA) is associated with poor clinical outcomes. Elevated serum LDH levels in chemoresistant patients further underscore the importance of metabolic reprogramming in the development of chemoresistance. Mechanistically, ChIP-seq, dual-luciferase reporter assays, and enzymatic colorimetric assays demonstrate that ERRα directly binds to the LDHA promoter region (5'-AGAAGGTCG-3'), activating its transcription and enhancing glycolysis and the production of its end-product, lactate. Scanning electron microscopy, immunofluorescence, Western Blot, and other molecular functional assays show that the ERRα/LDHA axis drives lactate accumulation, downregulates inflammasome-related proteins (NLRP3, caspase-1, GSDMD and GSDMD-N), thereby suppressing pyroptosis and promoting resistance to cisplatin, carboplatin, and paclitaxel in ovarian cancer cells. Pharmacological inhibition of ERRα with XCT790 restores sensitivity to chemotherapeutic agents. In a mouse xenograft model, targeting ERRα enhances the therapeutic efficacy of chemotherapy. Collectively, these findings reveal that the ERRα-LDHA axis increases lactate production, bridging glycolytic metabolism and the suppression of pyroptosis, thereby facilitating chemoresistance in ovarian cancer. Targeting the ERRα/LDHA pathway and developing ERRα inhibitors may represent promising strategies to overcome chemoresistance in ovarian cancer. ERRα targets the promoter region of LDHA, promoting its transcription and the production of the glycolytic product lactate, inhibiting the NLRP3/caspase-1/GSDMD pathway, reducing cell pyroptosis, and helping ovarian cancer cells resist the cytotoxic effects of carboplatin and paclitaxel. Created in BioRender. Ren, Y. (2025) https://BioRender.com/qeh0dw8 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.